Key Competitors - Ankylosing Spondylitis Industry

The worldwide ankylosis spondylitis market is anticipated to expand over the forecast period due to the rising prevalence of ankylosing spondylitis. Ankylosing spondylitis was reported to affect 96.9 out of every 100,000 people in Taiwan in March 2021 according to epidemiological data. The market's major players are concentrating on inorganic growth tactics including partnerships and collaborations, which are anticipated to propel market expansion over the forecast period. Inmagene Biopharmaceuticals, which focuses on the development of therapeutics for immunology-related diseases, and Affibody AB, which is engaged in the research and development of novel bi- and multi-specific next-generation biopharmaceuticals, announced the successful dosing of the first patient in the global ASPIRE phase 2 trial evaluating izokibep (IMG-020 or ABY-035) for the treatment of ankylosing spondylitis in (AS).

The global Ankylosing Spondylitis Market is estimated to be valued at US$ 4,864.3 million in 2021 and is expected to exhibit a CAGR of 8.2% during the forecast period (2021-2028).

Prominent Players in the Ankylosing Spondylitis Industry:

1.

Amgen Inc.

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.

2.

Abbvie Inc.

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc.

3.

Pfizer Inc.

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. on December 2022, Pfizer Presents Updated Favorable Elranatamab Data from Pivotal Phase 2 MagnetisMM-3 Trial, early and deep responses, and a manageable safety profile for elranatamab in heavily pretreated patients with advanced multiple myeloma

4.

Novartis AG

Novartis AG researches, develops, manufactures, and markets healthcare products in Switzerland and internationally. The company operates through two segments: Innovative Medicines and Sandoz. Novartis AG was incorporated in 1996 and is headquartered in Basel, Switzerland. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran, a therapy to reduce LDL cholesterol.

5.

Bristol-Myers Squibb Company

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products globally from 1887. The company was headquartered in New York, New York. In September, 2022 announced that the U.S. Food and Drug Administration (FDA) approved Sotyktu™ (deucravacitinib), a first-in-class, oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor, for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.

6.

Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide.  Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.

7.

Cipla Limited

Cipla Limited, together with its subsidiaries, manufactures and sells pharmaceutical products in India, the United States, South Africa, and internationally.  The company was incorporated in 1935 and is headquartered in Mumbai, India. Cipla Limited has a licensing agreement with Merck & Co., Inc. for the manufacturing and distribution of Molnupiravir, an investigational oral antiviral drug; a license agreement with Eli Lilly and Company for the manufacture and commercialization of the drug baricitinib for Covid-19 indication; and collaborations with Dr. Reddy's Laboratories Ltd, Sun Pharmaceutical Industries Limited, Emcure Pharmaceuticals Limited, and Torrent Pharmaceuticals Limited for the clinical trial of the investigational oral anti-viral drug Molnupiravir 

8.

UCB S.A.

UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases. The company was incorporated in 1925 and is headquartered in Brussels, Belgium.  It operates in the United States, Japan, Germany, rest of Europe, Spain, France, Italy, the United Kingdom, Ireland, China, Belgium, and internationally.

9.

Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company was founded in 1886 and is based in New Brunswick, New Jersey. On October 2022, The U.S. Food and Drug Administration (FDA) has approved Johnson & Johnson's  therapy for treating a type of multiple myeloma, the company said on Tuesday, giving another treatment option to patients with the incurable blood cancer.

*Definition -

A rare kind of inflammation called ankylosing spondylitis (AS) mostly affects the spine and can harm big joints in the body. It leads to inflammation in the vertebral joints, which results in excruciating pain and suffering.